ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "DMARDs"

  • Abstract Number: 137 • 2016 ACR/ARHP Annual Meeting

    Imaging Remission By Musculoskeletal Ultrasound Leads to a Better Functional Outcome – Results of the US Impera Study – US 7-Score Implementation Study in Early Rheumatoid Arthritis

    Anne-Marie Glimm1, Sarah Ohrndorf2, Imma Fischer3, Johannes Strunk4, Wolfgang A. Schmidt5, Wolfgang Hartung6, Herbert Kellner7, Horst Sattler8, Gabriela Schmittat1, GR Burmester9 and Marina Backhaus10, 1Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, 2Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, 3Biostatistik Tuebingen, Tuebingen, Germany, 4Department of Rheumatology, Hospital 'Porz am Rhein', Academic Hospital of the University of Cologne, Cologne, Germany, 5Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, 6Department of Rheumatology and Clinical Immunology, Asklepios Klinik Bad Abbach, Bad Abbach, Germany, 7Department of Internal Medicine – Rheumatologic Day Clinic, Krankenhaus Neuwittelsbach, Academic Hospital of Ludwig-Maximilians-University Munich, Munich, Germany, 8Internal Medicine and Rheumatology Practice, Bad Duerkheim, Bad Duerkheim, Germany, 9Charité – University Medicine Berlin, Berlin, Germany, 10Department of Rheumatology & Immunology, University Medicine Charit, Berlin, Germany

    Background/Purpose: Novel treat-to-target strategies present new challenges to treatment monitoring in rheumatoid arthritis (RA). To compare functional outcomes in early RA patients monitored by standard…
  • Abstract Number: 1981 • 2016 ACR/ARHP Annual Meeting

    A Pilot Pulsed Arterial Spin Labeling Study of Regional Cerebral Blood Flow in Response to Pain in RA, before and after DMARD Treatment

    Yvonne C. Lee1, Alexander Fine2, Ekaterina Protsenko3, Elena Massarotti4, Robert R. Edwards5, Vitaly Napadow6 and Marco Loggia3, 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 3Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA, 4Rheumatology Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, 5Anesthesiology, Brigham & Womens Hospital, Chestnut Hill, MA, 6Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA

    Background/Purpose: Although significant advances have been made in treating inflammation in RA, little is known about central nervous system (CNS) pain pathways in inflammatory arthritis.…
  • Abstract Number: 2578 • 2016 ACR/ARHP Annual Meeting

    Plasma Levels of Bone Morphogenetic Protein (BMP) Subgroups and Their Inhibitors (noggin, sclerostin) in Rheumatoid Arthritis Patients and Correlation with Disease Activity, Clinical and Radiographic Progression

    Ozge Kockara1, Merve Sibel Gungoren2, Erdem Karabulut3, Sebnem Ataman4 and Filiz Akbiyik2, 1Physical Medicine and Rehabilitation, Ankara University Faculty of Medicine, Ankara, Turkey, 2Medical Biochemistry, Hacettepe University Faculty of Medicine, Ankara, Turkey, 3Biostatistics, Hacettepe University Faculty of Medicine, Ankara, Turkey, 4Rheumatology Department, Ankara University Faculty of Medicine, Ankara, Turkey

    Background/Purpose: Progressive bone destruction occurs in rheumatoid arthritis (RA) due to imbalance of osteoblast/osteoclast activity. Bone morphogenetic proteins (BMPs) regenerate bone damage by stimulating the…
  • Abstract Number: 427 • 2015 ACR/ARHP Annual Meeting

    The Impact of Biologic Agent Initiation after 1 Versus 2 Prior Csdmards in Patients with Rheumatoid Arthritis

    Dimitrios A. Pappas1,2, Jenny Griffith3, Chitra Karki2, Mei Liu4, Joel M. Kremer5, Arijit Ganguli3 and Jeffrey D. Greenberg2,6, 1Columbia University, New York, NY, 2Corrona, LLC, Southborough, MA, 3AbbVie Inc., North Chicago, IL, 4352 Turnpike Rd, Corrona, LLC, Southborough, MA, 5Albany Medical College and The Center for Rheumatology, Albany, NY, 6NYU School of Medicine, New York, NY

    Background/Purpose: Patients with Rheumatoid Arthritis (RA) who don’t respond to conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) should be treated with biologic agents(1). The objective…
  • Abstract Number: 1488 • 2015 ACR/ARHP Annual Meeting

    Following the American College of Rheumatology Quality Guidelines Can Enhance the Safety of Rheumatoid Arthritis Patients Treated with Disease Modifying Drugs

    Delfina Bur1 and Humeira M. Badsha2, 1Dr. Humeira Badsha Medical Clinic, Dubai, United Arab Emirates, 2Rheumatology, Dr Humeira Badsha Medical Center, Dubai, United Arab Emirates

    Background/Purpose:  Adverse events (AEs) and serious adverse events (SAEs) from disease modifying drugs (DMARDs) for Rheumatoid Arthritis (RA) can result in significant morbidity and even…
  • Abstract Number: 2729 • 2015 ACR/ARHP Annual Meeting

    Clinical and Radiographic Outcome of Iguratimod for Rheumatoid Arthritis

    Tsuneo Kondo, Akiko Shibata, Ryota Sakai, Jun Kikuchi, Kentaro Chino, Ayumi Okuyama, Hirofumi Takei and Koichi Amano, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan

    Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…
  • Abstract Number: 498 • 2015 ACR/ARHP Annual Meeting

    Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey

    Gerolamo Bianchi1, Antonio Carletto2, Oscar M. Epis3, Crescenzio Scioscia4, Angelo Semeraro5, Chiara Donati6, Laura Bazzichi7, Giovanni Lapadula8, Luigi Sinigaglia9 and Andrea Lo Monaco10, 1Div Reumatologia, Ospedale La Colletta, Genoa, Italy, 2Rheumatology Unit, University of Verona, Verona, Italy, 3Rheumatology Unit, A.O. Ospedale Niguarda Ca' Granda, Milan, Italy, 4DIM - Sezione di Reuamtologia Università degli Studi di Bari "Aldo Moro", Bari, Italy, 5Unità Operativa di Reumatologia ASL Taranto, Taranto, Italy, 6Roche S.p.A., Monza, Italy, 7Division of Reumatology, Univeristy of Pisa, Pisa, Italy, 8D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, 9Rheumatology Dep, I.O.G. Pini, Milan, Italy, 10Ospedale S. Anna, Ferrara, Italy

    Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), the non-adherence to therapy may impair the clinical outcomes, being often associated with the disease flare and…
  • Abstract Number: 1491 • 2015 ACR/ARHP Annual Meeting

    Effects of Drug Induced Toxicity on Patient Reported Outcomes in Early Rheumatoid Arthritis Treated-to-Target Using Conventional Triple DMARD Therapy

    Nasir Wabe1, Michael Sorich2, Mihir Wechalekar2,3, Leslie Cleland3, Leah McWilliams3, Anita Lee4,5, Llew Spargo4, Robert Metcalf3, Cindy Hall4, Susanna Proudman4,5 and Michael D. Wiese6, 1School of Pharmacy and Medical Sciences and Sansom Institute for Health Research, University of South Australia, Adelaide, Australia, 2Flinders University, Adelaide, Australia, 3Royal Adelaide Hospital, Adelaide, Australia, 4Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, 5Discipline of Medicine, University of Adelaide, Adelaide, Australia, 6University of South Australia, Adelaide, Australia

    Background/Purpose: While the introduction of the treat-to-target (T2T) strategy is associated with lower disease activity scores in rheumatoid arthritis (RA), the potential for increased toxicity…
  • Abstract Number: 2731 • 2015 ACR/ARHP Annual Meeting

    Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry

    Dimitrios A. Pappas1,2, Ani John3, Carol J. Etzel2,4, Chitra Karki2, YouFu Li5, Joel M. Kremer6, Tmirah Haselkorn3 and Jeffrey D. Greenberg2,7, 1Columbia University, New York, NY, 2Corrona, LLC, Southborough, MA, 3Genentech, Inc, South San Francisco, CA, 4The University of Texas MD Anderson Cancer Center, Houston, TX, 5University of Massachusetts Medical School, Worcester, MA, 6Albany Medical College and The Center for Rheumatology, Albany, NY, 7NYU School of Medicine, New York, NY

    Background/Purpose: For patients with rheumatoid arthritis (RA), there are limited real-world data on factors that predict persistency on biologic therapy or whether use of biologics…
  • Abstract Number: 516 • 2015 ACR/ARHP Annual Meeting

    Immunological and Ultrasound Characteristics of Patients with Rheumatoid Arthritis in Clinical Remission – Can We Use These to Predict Outcomes?

    Hanna Gul1, Maria Jesus Isorna Porto2, Elizabeth M.A. Hensor3, Frederique Ponchel4, Richard J. Wakefield5 and Paul Emery6, 1Rheumatology, Leeds Institute of Rheumatology and Musculoskeletal Medicine, Leeds, United Kingdom, 2Internal Medicine, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, 3NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 4Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, 5University of Leeds, Leeds, United Kingdom, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Remission is the key treatment goal in rheumatoid arthritis (RA).  Although clinical remission is increasingly achieved, many patients progress both structurally and functionally. We…
  • Abstract Number: 1553 • 2015 ACR/ARHP Annual Meeting

    Effect of Drug Therapy on Net Cholesterol Efflux Capacity of HDL-Enriched Serum in Rheumatoid Arthritis

    Michelle J. Ormseth1, S. Louis Bridges Jr.2, Jeffrey R. Curtis3, Joseph F. Solus4, Patricia Yancey5, MacRae F. Linton6, Sean Davies6, L Jackson Roberts II7, Kasey C. Vickers6, Valentina Kon6, Sergio Fazio8, C Michael Stein6 and TETRAD Investigators, 1Department of Medicine, Division of Rheumatology, Vanderbilt University, Nashville, TN, 2Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4Clinical Pharmacology, Vanderbilt University, Nashville, TN, 5Medicine, Vanderbilt University, Nashville, TN, 6Vanderbilt University, Nashville, TN, 7Pharmacology, Vanderbilt University, Nashville, TN, 8Oregon Health and Science University, Portland, OR

    Background/Purpose: Patients with rheumatoid arthritis (RA) have increased coronary heart disease risk. Some RA therapies may modify this risk, but underlying mechanisms are unclear. The…
  • Abstract Number: 2742 • 2015 ACR/ARHP Annual Meeting

    Efficacy and Safety of Tofacitinib Monotherapy Versus Combination Therapy in a Latin American Subpopulation of Patients with Rheumatoid Arthritis: A Pooled Phase 3 Analysis

    Cristiano Zerbini1, Sebastiao Radominski2, Mario H. Cardiel3, Oswaldo Castañeda4, Ferope Romero5, Gustavo Citera6, Oscar Neira7, Dario Ponce de Leon8, Elaine Hoffman9 and Ricardo Rojo10, 1Centro Paulista de Investigação Clinica, São Paulo, Brazil, 2Universidade Federal do Paraná, Curitiba, Brazil, 3Centro de Investigacion Clinica de Morelia, Morelia, Mexico, 4Clínica Angloamericana, Lima, Peru, 5Hospital Arzobispo Loayza, Lima, Peru, 6Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 7Hospital del Salvador, Clínica Alemana, Santiago, Chile, 8Pfizer Inc, Lima, PA, Peru, 9Pfizer Inc, Groton, CT, 10Pfizer Inc, New York, NY

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post-hoc pooled analysis was designed to assess the efficacy and safety…
  • Abstract Number: 546 • 2015 ACR/ARHP Annual Meeting

    Adipokines and Insulin-like Growth Factor 1 As Predictors of Clinical and Radiographic Outcomes in Early Rheumatoid Arthritis

    Adrian Levitsky1, Kerstin Brismar2, Saedis Saevarsdottir3, Karen Hambardzumyan1, Anna Andersson1 and Ronald F. van Vollenhoven1, 1Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, 2Department of Molecular Medicine and Surgery, Unit of Growth and Metabolism, The Karolinska Institute, Stockholm, Sweden, 3Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Adipokines are cytokines/hormones primarily synthesized in white adipose tissue. In rheumatoid arthritis (RA), some adipokines have been associated with worse outcomes (1-3). The aim…
  • Abstract Number: 1634 • 2015 ACR/ARHP Annual Meeting

    The Effects of Glucocorticoids on the Efficacy of Tofacitinib As Monotherapy and in Combination Therapy with Nonbiologic Dmards: An Analysis of Data from Six Phase 3 Studies

    Roy Fleischmann1, Christina Charles-Schoeman2, Gerd Burmester3, Cristiano Zerbini4, Peter Nash5, Kenneth Kwok6, Koshika Soma7, Alan Mendelsohn8 and Eustratios Bananis8, 1Metroplex Clinical Research Center, Dallas, TX, 2University of California, Los Angeles, CA, 3Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, 4Centro Paulista de Investigação Clinica, São Paulo, Brazil, 5Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, 6Pfizer Inc, New York, NY, 7Pfizer Inc, Groton, CT, 8Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients with RA often receive concomitant treatment with glucocorticoids (GCs) to control…
  • Abstract Number: 2749 • 2015 ACR/ARHP Annual Meeting

    A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Patients (pts) with Rheumatoid Arthritis (RA): Preliminary Results

    Lei Zhou1, Robert Sikorski1, Seema Rogers1, Stefan Costin2, Mariusz Korkosz3, Maria Jaraczewska-Baumann4, Péterfai Éva5, Bernadette Rojkovich6, Janos Bartalos7, Emma Masteller1, Hong Xiang1, Brian Wong1 and Julie Hambleton1, 1Five Prime Therapeutics, Inc., South San Francisco, CA, 2PRA Heath Sciences, Berlin, Germany, 3Malopolskie Centrum Medyczne, The University Hospital in Krakow, Krakow, Poland, 4MedPolonia Sp. z o.o, Poznan, Poland, 5Drug Research Center, Balatonfüred, Hungary, 6Hospitaller Brothers of St. John of God, Budapest, Hungary, 7PRA Hungary Ltd, Budapest, Hungary

    Background/Purpose: FPA008 is a humanized IgG4 anti-CSF1R antibody that blocks the binding of CSF1 and IL34 ligands to CSF1R, resulting in inhibition of the activation…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology